Literature DB >> 1191267

Regulatory effects of fatty acyl-coenzyme A derivatives on phosphate-activated pig brain and kidney glutaminase in vitro.

E Kvamme, I A Torgner.   

Abstract

1. Fatty n-acyl-CoA derivatives in the concentration range 5muM-0.1mM and with 5-18 fatty acyl carbons have dual effects on phosphate-activated glutaminase from pig brain and kidney. Generally, fatty acyl-CoA derivatives in low concentrations activate the enzyme, but inhibit at higher concentrations; phosphate and citrate potentiate the activation, displaying positive co-operatively, and protect against inactivation. The fatty acyl-CoA derivatives affect glutaminase similarly to Bromothymol Blue, but differently from acetyl-CoA, which activates the enzyme only at very low phosphate or citrate concentrations. 2. Saturated fatty acyl-CoA derivatives, with 5-10 fatty acyl carbons, only activate the enzyme in the concentration range 0-0.1 mM. When the fatty acyl chain is elongated, the fatty acyl-CoA derivatives gradually become more powerful inhibitors of glutaminase at the expense of their activating capacity. In particular, palmitoyl-CoA and stearoyl-CoA are strong inhibitors at concentrations (10 muM) at which the corresponding free fatty acids and fatty acyl-carnitine derivatives have no effect. 3. The unsaturated fatty acyl-CoA derivatives, oleoyl-CoA and linoleoyl-CoA, behave as potent activators in the lower part of the concentration range tested (0-0.05mM), and as inhibitors in the upper part of this range (0.02-0.10mM). Oleic acid and linoleic acid have similar properties, but their activating capacity is less pronounced. 4. Phosphate both prevented and reversed the inhibition, but no restoration of activity was possible once the enzyme became inactivated. 5. By changing the pH from 7.0 to 8.0 the activating capacity of the fatty acyl-CoA derivatives is increased, as is their concentration range for activation. 6. The fatty acyl-CoA derivatives are somewhat more potent activator for brain glutaminase, but otherwise they affect the two enzymes similarly.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1191267      PMCID: PMC1165595          DOI: 10.1042/bj1490083

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  24 in total

1.  The mechanism of ammonia excretion during ammonium chloride acidosis.

Authors:  F C RECTOR; D W SELDIN; J H COPENHAVER
Journal:  J Clin Invest       Date:  1955-01       Impact factor: 14.808

2.  Modulators of glutaminase activity.

Authors:  H Weil-Malherbe
Journal:  J Neurochem       Date:  1972-10       Impact factor: 5.372

3.  Phosphate-dependent effects of palmityl-CoA and stearyl-CoA on phosphate-activated pig brain and pig kidney glutaminase.

Authors:  E Kvamme; I A Torgner
Journal:  FEBS Lett       Date:  1974-10-15       Impact factor: 4.124

4.  Reversible inhibition of mitochondrial adenosine diphosphate phosphorylation by long chain acyl coenzyme A esters.

Authors:  S V Pande; M C Blanchaer
Journal:  J Biol Chem       Date:  1971-01-25       Impact factor: 5.157

5.  Palmityl coenzyme A inhibition of fatty acid synthesis. Relief by bovine serum albumin and mycobacterial polysaccharides.

Authors:  H Knoche; T W Esders; K Koths; K Bloch
Journal:  J Biol Chem       Date:  1973-04-10       Impact factor: 5.157

6.  Reversal by CoA of palmityl-CoA inhibition of long chain acyl-CoA synthetase activity.

Authors:  S V Pande
Journal:  Biochim Biophys Acta       Date:  1973-04-13

7.  Riboflavin 5'-phosphate: a potent activator or brain glutaminase.

Authors:  H Weil-Malherbe; G D Beall
Journal:  J Neurochem       Date:  1970-07       Impact factor: 5.372

8.  Glutaminase from pig renal cortex. II. Activation by inorganic and organic anions.

Authors:  G Svenneby; B Tveit; E Kvamme
Journal:  J Biol Chem       Date:  1970-04-25       Impact factor: 5.157

9.  Kinetic properties of glutaminase from pig renal cortex.

Authors:  B Tveit; G Svenneby; E Kvamme
Journal:  Eur J Biochem       Date:  1970-06

10.  Glutaminase from pig kidney, an allosteric protein.

Authors:  E Kvamme; B Tveit; G Svenneby
Journal:  Biochem Biophys Res Commun       Date:  1965-09-08       Impact factor: 3.575

View more
  8 in total

Review 1.  Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms.

Authors:  Kenneth E Miller; E Matthew Hoffman; Mathura Sutharshan; Ruben Schechter
Journal:  Pharmacol Ther       Date:  2011-01-26       Impact factor: 12.310

2.  Evaluating the Analgesic Effect of the GLS Inhibitor 6-Diazo-5-Oxo-L-Norleucine in Vivo.

Authors:  Heith A Crosby; Kenneth E Miller
Journal:  Pharm Pharmacol Int J       Date:  2016-01-08

3.  Ammonia metabolism during acid-base disturbance.

Authors:  D J O'Donovan
Journal:  Ir J Med Sci       Date:  1985-07       Impact factor: 1.568

Review 4.  Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain.

Authors:  E Kvamme; B Roberg; I A Torgner
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

5.  Calcium stimulation of glutamine hydrolysis in synaptosomes from rat brain.

Authors:  E Kvamme; G Svenneby; I A Torgner
Journal:  Neurochem Res       Date:  1983-01       Impact factor: 3.996

6.  Functional intracellular glutaminase activity in intact astrocytes.

Authors:  H R Zielke; J T Tildon; C L Zielke; P J Baab; M E Landry
Journal:  Neurochem Res       Date:  1989-04       Impact factor: 3.996

7.  Loss of glutaminase-positive cortical neurons in Alzheimer's disease.

Authors:  H Akiyama; P L McGeer; S Itagaki; E G McGeer; T Kaneko
Journal:  Neurochem Res       Date:  1989-04       Impact factor: 3.996

8.  Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.

Authors:  Yue-Zhi Lee; Cheng-Wei Yang; Hsin-Yu Chang; Hsing-Yu Hsu; Ih-Shen Chen; Hsun-Shuo Chang; Chih-Hao Lee; Jinq-chyi Lee; Chidambaram Ramesh Kumar; Ya-Qi Qiu; Yu-Sheng Chao; Shiow-Ju Lee
Journal:  Oncotarget       Date:  2014-08-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.